TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12729080

Group type: EXPERIMENTAL
Intervention: 50% w/v silver nitrate solution
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 25% w/v silver nitrate solution
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 10% w/v silver nitrate solution
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 2% w/v silver nitrate solution
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 50% w/v silver nitrate solution buffered to pH 6
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 50% w/v silver nitrate solution at pH 3.4, 4.2, 4.4, and 4.9
Number of subjects: 4
Study: 10426831

Group type: EXPERIMENTAL
Intervention: High-dose sibrafiban (dosage based on body weight and renal function, administered every 12 hours)
Number of subjects: 9000

Group type: EXPERIMENTAL
Intervention: Low-dose sibrafiban (dosage based on body weight and renal function, administered every 12 hours)
Number of subjects: 9000

Group type: COMPARATOR
Intervention: Aspirin (80 mg every 12 hours)
Number of subjects: 9000

Group type: EXPERIMENTAL
Intervention: All treatment groups (including aspirin and both doses of sibrafiban)
Number of subjects: 9000
Study: 8718440

Group type: EXPERIMENTAL
Intervention: Quarterly comparisons with feedback
Number of subjects: 124

Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 124
Study: 1831504

Group type: EXPERIMENTAL
Intervention: Tetracycline fiber
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control fiber
Number of subjects: 113

Group type: COMPARATOR
Intervention: Scaling with root planing
Number of subjects: 113

Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 113
Study: 6961944

Group type: EXPERIMENTAL
Intervention: Hypertransfusion (Hb: 16-18 g/dl)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Normotransfusion (Hb: 12-14 g/dl)
Number of subjects: 19
Study: 31736460

Group type: EXPERIMENTAL
Intervention: 10 mg rapamycin (RET + RAP)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo (RET + PBO)
Number of subjects: 75

Group type: COMPARATOR
Intervention: 10 mg rapamycin without subsequent retrieval (NO RET + RAP)
Number of subjects: 75
Study: 31253485

Group type: EXPERIMENTAL
Intervention: Estradiol ointment
Number of subjects: 33

Group type: COMPARATOR
Intervention: Testosterone ointment
Number of subjects: 33

Group type: COMPARATOR
Intervention: Neutral base ointment
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 33
Study: 29149038

Group type: EXPERIMENTAL
Intervention: Hunger training with booklet entry (at least 60 days of recommended 63 days)
Number of subjects: 50
Study: 25734980

Group type: EXPERIMENTAL
Intervention: Intravaginal prasterone (6.5 mg daily for 12 weeks)
Number of subjects: 0
Study: 23494214

Group type: EXPERIMENTAL
Intervention: MenACWY-TT
Number of subjects: 400

Group type: COMPARATOR
Intervention: MenPS
Number of subjects: 400
Study: 21695210

Group type: EXPERIMENTAL
Intervention: PCV7 (2+1 doses)
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: PCV7 (2 doses)
Number of subjects: 1005

Group type: COMPARATOR
Intervention: No PCV7 (controls)
Number of subjects: 1005
Study: 19929217

Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg for 3 months
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 99
Study: 16709427

Group type: EXPERIMENTAL
Intervention: Individualized feedback letters generated by computerized expert‐system technology
Number of subjects: 485

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 485
Study: 15223851

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Vardenafil (10 mg)
Number of subjects: 35
Study: 11419681

Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 82

Group type: COMPARATOR
Intervention: Artesunate
Number of subjects: 82
Study: 9413772

Group type: EXPERIMENTAL
Intervention: Bier's block
Number of subjects: 142

Group type: COMPARATOR
Intervention: Haematoma block
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Alkalinised haematoma block
Number of subjects: 142

Group type: COMPARATOR
Intervention: Non-alkalinised haematoma block
Number of subjects: 142
Study: 8496540

Group type: EXPERIMENTAL
Intervention: High osmolality contrast medium
Number of subjects: 505

Group type: COMPARATOR
Intervention: Low osmolality contrast medium
Number of subjects: 505
Study: 2957971

Group type: EXPERIMENTAL
Intervention: Aminohydroxybutylidene diphosphonate (2.5 mg/d intravenously for five days)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Dichloromethylene diphosphonate (300 mg/d intravenously for seven days, followed by 100 mg/d intramuscularly for ten days)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Aminohydroxybutylidene diphosphonate
Number of subjects: 28

Group type: COMPARATOR
Intervention: Dichloromethylene diphosphonate
Number of subjects: 28
Study: 29391492

Group type: EXPERIMENTAL
Intervention: Distal-emphasized robotic rehabilitation (D-IMT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Proximal-emphasized robotic rehabilitation (P-IMT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control treatment (CT)
Number of subjects: 40
Study: 26950307

Group type: EXPERIMENTAL
Intervention: Lower dose (LD) adalimumab weekly
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Higher dose (HD) adalimumab weekly
Number of subjects: 188

Group type: COMPARATOR
Intervention: Every other week (EOW) adalimumab
Number of subjects: 188
Study: 25213147

Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus rhamnosus HN001)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 23758800

Group type: EXPERIMENTAL
Intervention: Intravenous ghrelin (2 μg/kg, n = 10)
Number of subjects: 20
Study: 20923392

Group type: EXPERIMENTAL
Intervention: Fresh Frozen Plasma (FFP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 20% Human Albumin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: FFP, Albumin, Saline (all groups)
Number of subjects: 60
Study: 18158364

Group type: EXPERIMENTAL
Intervention: VOCs exposure
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: VOCs+O3 exposure
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Ambient or filtered air with a 1‐minute spike of VOCs (masked clean air)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Speech stressor
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Simple arithmetic
Number of subjects: 130
Study: 16374881

Group type: EXPERIMENTAL
Intervention: EZ-STEP sequence
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conventional MRA
Number of subjects: 15
Study: 12969204

Group type: EXPERIMENTAL
Intervention: Caffeine citrate 3 mg/kg
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Caffeine citrate 15 mg/kg
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Caffeine citrate 30 mg/kg
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Caffeine citrate 15 mg/kg and 30 mg/kg
Number of subjects: 127
Study: 11050638

Group type: EXPERIMENTAL
Intervention: Mangafodipir trisodium (MnDPDP) injection (5 micromol/kg IV)
Number of subjects: 404
Study: 8626981

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TA) 400 micrograms
Number of subjects: 85

Group type: COMPARATOR
Intervention: Propellant (placebo)
Number of subjects: 85
Study: 1462920

Group type: EXPERIMENTAL
Intervention: SPECT imaging with preprocessing masking technique
Number of subjects: 10

Group type: COMPARATOR
Intervention: SPECT imaging without preprocessing masking technique (before masking)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: SPECT imaging with preprocessing masking technique (after masking)
Number of subjects: 10
Study: 6734050

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30947634

Group type: EXPERIMENTAL
Intervention: Multiple Calls Intervention (MCI)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Single Call Intervention (SCI)
Number of subjects: 142
Study: 30316482

Group type: EXPERIMENTAL
Intervention: Self-directed Triple P Online
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Telephone-supported Triple P Online
Number of subjects: 183

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 183
Study: 27049234

Group type: EXPERIMENTAL
Intervention: Asthma Counseling (AC) intervention
Number of subjects: 182
Study: 24106326

Group type: EXPERIMENTAL
Intervention: Rigid thoracoscopy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Semirigid thoracoscopy
Number of subjects: 90
Study: 22938019

Group type: EXPERIMENTAL
Intervention: Use of the CORAL Decision Aid (DA) in addition to treatment as usual
Number of subjects: 80

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 80
Study: 19706219

Group type: EXPERIMENTAL
Intervention: Educational intervention delivered by local health-care providers
Number of subjects: 599

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 599
Study: 17941770

Group type: EXPERIMENTAL
Intervention: 6F Double‐J stent (group 2)
Number of subjects: 48

Group type: COMPARATOR
Intervention: 18F Re‐entry nephrostomy tube (group 1)
Number of subjects: 48
Study: 15699482

Group type: EXPERIMENTAL
Intervention: OSI‐211 1.8 mg/m(2)/d administered by 30‐minute intravenous infusion on days 1, 2, and 3 every 3 weeks
Number of subjects: 81

Group type: COMPARATOR
Intervention: OSI‐211 2.4 mg/m(2)/d administered by 30‐minute intravenous infusion on days 1 and 8 every 3 weeks
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Arm A (OSI‐211 1.8 mg/m(2)/d)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Arm B (OSI‐211 2.4 mg/m(2)/d)
Number of subjects: 81
Study: 12475836

Group type: EXPERIMENTAL
Intervention: Single-dose group (7.5 mg albuterol)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Multidose group (2.5 mg albuterol, three doses)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Single-dose group
Number of subjects: 94

Group type: COMPARATOR
Intervention: Multidose group
Number of subjects: 94
Study: 10402692

Group type: EXPERIMENTAL
Intervention: Five-factor model derived from principal components analysis in study 1
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: Revised model tested in study 2
Number of subjects: 780

Group type: COMPARATOR
Intervention: Single-factor model, Kellner's nine-factor model, Ferguson and Daniel's four-factor model, Stewart and Watt's four-factor model
Number of subjects: 780
Study: 7486842

Group type: EXPERIMENTAL
Intervention: Fluoxetine (group A)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (group B)
Number of subjects: 42
Study: 2102064

Group type: EXPERIMENTAL
Intervention: PDRN 5 mg ovules
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 90434

Group type: EXPERIMENTAL
Intervention: Phytodrug (Sabal serrulatum)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 74

Group type: COMPARATOR
Intervention: Phytodrug (Sabal serrulatum) with placebo
Number of subjects: 74
Study: 29629665

Group type: EXPERIMENTAL
Intervention: Multiphasic cancer screening (including PSA, digital rectal examination, chest x‐ray, flexible sigmoidoscopy, CA125, transvaginal ultrasound)
Number of subjects: 154897

Group type: EXPERIMENTAL
Intervention: Multiphasic cancer screening
Number of subjects: 154897
Study: 26682578

Group type: EXPERIMENTAL
Intervention: Stripping technique
Number of subjects: 51

Group type: COMPARATOR
Intervention: Combined excisional/ablative technique
Number of subjects: 51
Study: 24155264

Group type: EXPERIMENTAL
Intervention: Direct resin composite restorations
Number of subjects: 157

Group type: COMPARATOR
Intervention: Indirect resin composite restorations
Number of subjects: 157
Study: 24430035

Group type: EXPERIMENTAL
Intervention: Cytoflavin (2 pills twice per day, total 4 pills daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard antidepressant therapy (control)
Number of subjects: 100
Study: 20658369

Group type: EXPERIMENTAL
Intervention: One-day bowel preparation with probiotics
Number of subjects: 60

Group type: COMPARATOR
Intervention: 3-day conventional bowel preparation
Number of subjects: 60
Study: 18721256

Group type: EXPERIMENTAL
Intervention: Miglitol administered after meals for 3 months
Number of subjects: 31

Group type: COMPARATOR
Intervention: Miglitol administered before meals for 3 months
Number of subjects: 31
Study: 16845576

Group type: EXPERIMENTAL
Intervention: Denver Model (12 1-h weekly sessions of therapy and daily 1-h home intervention)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PROMPT (12 1-h weekly sessions of therapy and daily 1-h home intervention)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 10
Study: 11433855

Group type: EXPERIMENTAL
Intervention: Air abrasion treatment of questionable incipient carious lesions
Number of subjects: 223

Group type: COMPARATOR
Intervention: Control group (observed but untreated)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Air abrasion treatment of carious lesions in control group
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Preventive resin-based composite restorations in treatment group
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Sealants in treatment group
Number of subjects: 223
Study: 10028299

Group type: EXPERIMENTAL
Intervention: 35 mu kg‐1 rFVIIa
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: 70 mu kg‐1 rFVIIa
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Both dosages of rFVIIa
Number of subjects: 116
Study: 7508071

Group type: EXPERIMENTAL
Intervention: Aprotinin (high-dose, up to 7 million KIU)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 2735752

Group type: EXPERIMENTAL
Intervention: 600 micrograms of selenium-enriched yeast
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: 600 micrograms of selenium-enriched yeast plus 600 IU of vitamin E
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 1313484

Group type: EXPERIMENTAL
Intervention: Fibre (7 g/day)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 629867

Group type: EXPERIMENTAL
Intervention: PUVA plus topical corticosteroids
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Dithranol plus PUVA
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Tar plus PUVA
Number of subjects: 116

Group type: COMPARATOR
Intervention: PUVA alone
Number of subjects: 116
Study: 31280648

Group type: EXPERIMENTAL
Intervention: Central mean arterial pressure (+11.3 mm Hg)
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Central pulse pressure (+15.2 mm Hg)
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Augmentation ratio (+7.0%)
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Aortic pulse wave velocity (+1.66 m/s)
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Forward pulse wave (+10.0 mm Hg)
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Backward pulse wave (+8.5 mm Hg)
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Central diastolic blood pressure
Number of subjects: 735
Study: 28693535

Group type: EXPERIMENTAL
Intervention: Alfredson isolated eccentric training program (n=43)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Silbernagel combined concentric-eccentric program (n=43)
Number of subjects: 86
Study: 26433183

Group type: EXPERIMENTAL
Intervention: Albendazole treatment (8 days) with prednisone
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo with prednisone
Number of subjects: 178
Study: 23380186

Group type: EXPERIMENTAL
Intervention: GM-CSF (2 ng/mL in embryo culture medium)
Number of subjects: 1332

Group type: COMPARATOR
Intervention: Control (embryo culture medium without GM-CSF)
Number of subjects: 1332
Study: 21552714

Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment (scaling and root planning, professional prophylaxis, oral hygiene instruction)
Number of subjects: 33

Group type: COMPARATOR
Intervention: No intervention (received professional prophylaxis and oral hygiene instruction during pregnancy, referred for treatment after delivery)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment
Number of subjects: 33

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 33
Study: 19407444

Group type: EXPERIMENTAL
Intervention: terutroban (30 mg/day)
Number of subjects: 19119

Group type: COMPARATOR
Intervention: aspirin (100 mg/day)
Number of subjects: 19119
Study: 17265131

Group type: EXPERIMENTAL
Intervention: Heroin users with a history of overdose before ATOS
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Heroin users with overdose experience in any 1 year
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Overall heroin users
Number of subjects: 387
Study: 14673517

Group type: EXPERIMENTAL
Intervention: High-impact exercise intervention for 18 months
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (31 women)
Number of subjects: 65
Study: 12361194

Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg once daily (o.d.)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg o.d.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Losartan 50 mg o.d.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Valsartan 80 mg o.d.
Number of subjects: 24
Study: 9719120

Group type: EXPERIMENTAL
Intervention: Radiation plus Prednisone (R+P)
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Radiation alone (R)
Number of subjects: 777

Group type: COMPARATOR
Intervention: No further treatment (NT)
Number of subjects: 777
Study: 8109547

Group type: EXPERIMENTAL
Intervention: Nicotinic acid (0.5 to 1.0 g twice daily)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg at bedtime)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 158

Group type: COMPARATOR
Intervention: Nicotinic acid
Number of subjects: 158

Group type: COMPARATOR
Intervention: Pravastatin
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 2486560

Group type: EXPERIMENTAL
Intervention: Unilateral cervical adjustments on the side of most restricted end-range
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention or preliminary palpatory and set-up procedures without thrust
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unilateral cervical adjustments on the less restricted side
Number of subjects: 0
Study: 813161

Group type: EXPERIMENTAL
Intervention: Rynacrom (sodium cromoglycate)
Number of subjects: 39
Study: 27701082

Group type: EXPERIMENTAL
Intervention: Authoritarian parenting style
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Permissive parenting style
Number of subjects: 300

Group type: COMPARATOR
Intervention: Authoritative parenting style
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Maternal stress in parents of bullies and victims
Number of subjects: 300
Study: 28258027

Group type: EXPERIMENTAL
Intervention: Usual care plus DVD (DVD group, n=77)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care alone (control group, n=73)
Number of subjects: 150
Study: 25880012

Group type: EXPERIMENTAL
Intervention: CIGB-300 70 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: CIGB-300 35 mg
Number of subjects: 14
Study: 23591160

Group type: COMPARATOR
Intervention: Pemetrexed as second-line treatment after observation
Number of subjects: 464

Group type: COMPARATOR
Intervention: Pemetrexed as second-line treatment after gemcitabine maintenance
Number of subjects: 464

Group type: COMPARATOR
Intervention: Pemetrexed as second-line treatment after erlotinib maintenance
Number of subjects: 464
Study: 21114584

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg, intravenous)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 14
Study: 19161649

Group type: EXPERIMENTAL
Intervention: Immediate group (behavioural intervention promoting lower-GI foods)
Number of subjects: 109
Study: 17301091

Group type: EXPERIMENTAL
Intervention: 10 mg of montelukast
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 14982484

Group type: EXPERIMENTAL
Intervention: Fibrotic bowel tissue from patients with radiation enteritis
Number of subjects: 12

Group type: COMPARATOR
Intervention: Healthy bowel tissue samples from patients without radiation enteritis
Number of subjects: 12
Study: 11507800

Group type: EXPERIMENTAL
Intervention: Braun Oral‐B D8
Number of subjects: 113

Group type: COMPARATOR
Intervention: Colgate Actibrush
Number of subjects: 113
Study: 9758289

Group type: EXPERIMENTAL
Intervention: Trovafloxacin 200 mg
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Trovafloxacin 100 mg
Number of subjects: 419

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanic acid
Number of subjects: 419
Study: 7846905

Group type: EXPERIMENTAL
Intervention: En bloc resection (group I)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (group II)
Number of subjects: 27
Study: 2854365

Group type: EXPERIMENTAL
Intervention: Mefloquine-sulphadoxine-pyrimethamine (MSP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 0
Study: 28057378

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (35% fat, 22% MUFA)
Number of subjects: 424

Group type: COMPARATOR
Intervention: Low-fat diet (28% fat, 12% MUFA)
Number of subjects: 424
Study: 27858526

Group type: EXPERIMENTAL
Intervention: 1st-person narration
Number of subjects: 0

Group type: COMPARATOR
Intervention: 3rd-person narration
Number of subjects: 0
Study: 23710817

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 24
Study: 22624652

Group type: EXPERIMENTAL
Intervention: Individualized nutritional care with visits from a trained nutritionist 4-8 times at home, tailored nutritional care, protein and nutrient-enriched complementary drinks, vitamin D 20 μg/day for one year
Number of subjects: 202

Group type: COMPARATOR
Intervention: Written guide on nutrition for older people
Number of subjects: 202
Study: 19557391

Group type: EXPERIMENTAL
Intervention: Double bundle (DB) technique
Number of subjects: 40

Group type: COMPARATOR
Intervention: Single bundle (SB) technique
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both techniques (DB and SB)
Number of subjects: 40
Study: 19260458

Group type: EXPERIMENTAL
Intervention: Closure with Berci's needle
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard hand-sutured technique
Number of subjects: 100
Study: 15700052

Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg daily) plus calcium (1000 mg daily)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Calcium (1000 mg daily)
Number of subjects: 19